Protein Aggregation Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Protein aggregation inhibitors are small molecules and biological agents designed to prevent or reverse the pathological accumulation of misfolded proteins in neurodegenerative diseases. These therapies target the fundamental process underlying disorders like Alzheimer's disease (Aβ, tau), Parkinson's disease (α-synuclein), Huntington's disease (mutant huntingtin), ALS (SOD1, TDP-43), and prion diseases. aggregation Several inhibitors have reached clinical trials, with some showing promise in modifying disease progression. [1]
Aggregation inhibitors work through multiple mechanisms: [2]
| Mechanism | Description | [3]
|-----------|-------------| [4]
| Nucleation Inhibition | Prevent initial protein misfolding and oligomerization | [5]
| Oligomer Stabilization | Shift equilibrium toward non-toxic oligomers | [6]
| Aggregate Disassembly | Promote clearance of existing aggregates | [7]
| Seeding Blocking | Prevent templated spread of pathology |
| Proteostasis Enhancement | Upregulate cellular clearance pathways |
| Trial | Drug | Target | Phase | Status | Indication |
|---|---|---|---|---|---|
| NCT02245568 | TRx-0237 | Tau | III | Completed | Alzheimer's disease |
| NCT01680238 | Methylene Blue | Tau | II | Completed | Alzheimer's disease |
| NCT03135483 | Anle138b | α-syn | I | Completed | Parkinson's disease |
| NCT01720537 | Azeliragon | RAGE | III | Failed | Alzheimer's disease |
| NCT00788034 | Semaglintide | Aβ | III | Failed | Alzheimer's disease |
| Compound | Target | Evidence Level |
|---|---|---|
| Curcumin | Aβ, τ, α-syn | Preclinical |
| Resveratrol | Aβ | Clinical trials |
| Epigallocatechin-3-gallate | Aβ | Phase II |
| Oleocanthal | Aβ | Preclinical |
| Silibinin | α-syn | Preclinical |
Current research focuses on:
The study of Protein Aggregation Inhibitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Wischik CM, et al. Tau aggregation inhibitor therapy for Alzheimer's disease. 2019. ↩︎
Levin J, et al. The oligomer modulator anle138b in Parkinson's disease. 2022. ↩︎
Bieschke J, et al. EGCG remodels mature α-synuclein and amyloid-β fibrils. 2021. ↩︎
Miller DW, et al. Targeting protein aggregation in neurodegeneration. 2020. ↩︎
Schedin-Weiss S, et al. Lysosome-targeted aggregation inhibitors. 2022. ↩︎
Nguyen PH, et al. Amyloid inhibitors and the nucleation-elongation model. 2021. ↩︎
Sarell CJ, et al. Antisense and peptide approaches. 2023. ↩︎